Form 4: Avidity CCO Disposes Shares in Novartis Merger

Avidity Biosciences' Chief Commercial Officer, Eric Mosbrooker, disposed of common stock and stock options as part of the previously announced merger with Novartis AG.

Summary

• Eric Mosbrooker, Chief Commercial Officer of Avidity Biosciences, Inc., reported the disposition of common stock and stock options.
• The transactions occurred on February 27, 2026, pursuant to the terms of an Agreement and Plan of Merger.
• The Merger Agreement, dated October 25, 2025, is between Novartis AG, Ajax Acquisition Sub, Inc., and Avidity Biosciences, Inc.
• Mosbrooker disposed of 79,413 shares of Common Stock, including shares issuable upon settlement of previously reported restricted stock units.
• He also disposed of 177,188 stock options with an exercise price of $9.05 and 50,000 stock options with an exercise price of $31.42.
• The options were disposed of in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over their respective exercise prices.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively as it confirms the execution of a merger agreement, indicating a successful exit for Avidity Biosciences shareholders at a premium, which is generally favorable for investors.

Positives

• The disposition of securities by the Chief Commercial Officer confirms the progression and execution of the merger with Novartis AG.
• Shareholders, including insiders, are realizing value from the acquisition at a merger consideration of $72.00 per share.

Negatives

• The company will cease to exist as an independent publicly traded entity following the completion of the merger.

Future Outlook

Avidity Biosciences' independent future outlook is limited as the company is being acquired by Novartis AG, with its operations expected to be integrated into the acquiring entity.

Industry Context

StockSavvy.ai notes that this Form 4 filing is a standard procedural disclosure following a definitive merger agreement, reflecting the conversion of insider equity holdings into cash as the acquisition progresses. Such transactions are common in the biotechnology and pharmaceutical sectors, where M&A activity is a significant driver of value realization.

Stakeholder Impact

• Shareholders will receive cash consideration of $72.00 per share for their common stock and in-the-money options, realizing value from their investment.
• Employees holding stock options, such as the Chief Commercial Officer, are converting their equity into cash based on the merger terms.

Next Steps

• Completion of the merger with Novartis AG, leading to Avidity Biosciences becoming an indirect wholly-owned subsidiary of Novartis.

Key Dates

Keywords

Avidity Biosciences, RNAM, Novartis, Merger, Acquisition, Insider Transaction, Form 4, Stock Options, Common Stock, Chief Commercial Officer